Exponent, Inc. (NASDAQ:EXPO – Get Free Report) CEO Catherine Corrigan sold 4,119 shares of Exponent stock in a transaction on Monday, June 15th. The stock was sold at an average price of $57.13, for a total value of $235,318.47. Following the sale, the chief executive officer directly owned 106,670 shares of the company’s stock, valued at $6,094,057.10. This represents a 3.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Catherine Corrigan also recently made the following trade(s):
- On Friday, May 15th, Catherine Corrigan sold 4,194 shares of Exponent stock. The shares were sold at an average price of $54.06, for a total transaction of $226,727.64.
- On Wednesday, April 15th, Catherine Corrigan sold 3,909 shares of Exponent stock. The stock was sold at an average price of $67.70, for a total transaction of $264,639.30.
Exponent Stock Down 0.6%
Shares of Exponent stock opened at $57.01 on Thursday. The stock has a market capitalization of $2.77 billion, a price-to-earnings ratio of 26.52 and a beta of 0.72. Exponent, Inc. has a twelve month low of $51.91 and a twelve month high of $81.95. The company has a 50-day simple moving average of $61.39 and a two-hundred day simple moving average of $67.75.
Exponent Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 18th. Shareholders of record on Friday, June 5th will be paid a dividend of $0.31 per share. This represents a $1.24 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, June 5th. Exponent’s dividend payout ratio (DPR) is 57.67%.
Wall Street Analyst Weigh In
EXPO has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. cut their target price on Exponent from $95.00 to $80.00 and set an “overweight” rating for the company in a research report on Friday, May 15th. UBS Group reaffirmed a “neutral” rating and issued a $75.00 price target on shares of Exponent in a research note on Tuesday, June 2nd. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Exponent in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Exponent currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.50.
Get Our Latest Stock Analysis on Exponent
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in EXPO. NewEdge Advisors LLC boosted its holdings in shares of Exponent by 3,191.2% in the 1st quarter. NewEdge Advisors LLC now owns 4,476 shares of the business services provider’s stock valued at $292,000 after purchasing an additional 4,340 shares in the last quarter. Summitry LLC raised its holdings in shares of Exponent by 10.2% during the 1st quarter. Summitry LLC now owns 7,806 shares of the business services provider’s stock worth $509,000 after buying an additional 725 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Exponent by 0.5% during the 1st quarter. Bank of America Corp DE now owns 539,793 shares of the business services provider’s stock worth $35,221,000 after buying an additional 2,707 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Exponent by 26.5% during the 1st quarter. California State Teachers Retirement System now owns 60,432 shares of the business services provider’s stock worth $3,943,000 after buying an additional 12,655 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in shares of Exponent during the 1st quarter worth $353,000. 92.37% of the stock is owned by institutional investors.
Exponent Company Profile
Exponent, Inc (NASDAQ: EXPO) is an engineering and scientific consulting firm that offers multidisciplinary analysis and advisory services to clients across a range of industries. The company’s expertise spans mechanical, materials and corrosion engineering, civil and structural engineering, electrical engineering, industrial hygiene, toxicology and health sciences, and failure analysis. Exponent provides support for product design, performance evaluation, litigation consulting, and regulatory compliance, helping manufacturers, insurers, law firms and government agencies address complex technical challenges.
Founded in 1967 in Menlo Park, California, Exponent has grown from a small failure-analysis laboratory into a global consulting practice.
Recommended Stories
- Five stocks we like better than Exponent
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.
